{
    "company_name": "Kiniksa Pharmaceuticals, Ltd.",
    "file_name": "74c690176ce433301f4d1e808bb002a2f4dc321a",
    "data_points": [
        {
            "company_name": "Kiniksa Pharmaceuticals, Ltd.",
            "industry": "Pharmaceuticals",
            "metric_type": "Number of drugs on the market (approved)",
            "metric_src_pdf_page": [
                7,
                8
            ]
        },
        {
            "company_name": "Kiniksa Pharmaceuticals, Ltd.",
            "industry": "Pharmaceuticals",
            "metric_type": "Number of compounds in Phase I",
            "metric_src_pdf_page": [
                8
            ]
        },
        {
            "company_name": "Kiniksa Pharmaceuticals, Ltd.",
            "industry": "Pharmaceuticals",
            "metric_type": "Number of compounds in Phase II",
            "metric_src_pdf_page": [
                8
            ]
        },
        {
            "company_name": "Kiniksa Pharmaceuticals, Ltd.",
            "industry": "Pharmaceuticals",
            "metric_type": "Number of compounds in Phase III",
            "metric_src_pdf_page": [
                8
            ]
        },
        {
            "company_name": "Kiniksa Pharmaceuticals, Ltd.",
            "industry": "Pharmaceuticals",
            "metric_type": "Clinical trial sites operating at year-end",
            "metric_src_pdf_page": [
                8
            ]
        },
        {
            "company_name": "Kiniksa Pharmaceuticals, Ltd.",
            "industry": "Pharmaceuticals",
            "metric_type": "Inventory of active pharmaceutical ingredients",
            "metric_src_pdf_page": [
                8
            ]
        },
        {
            "company_name": "Kiniksa Pharmaceuticals, Ltd.",
            "industry": "Pharmaceuticals",
            "metric_type": "Size of sales force (year-end)",
            "metric_src_pdf_page": [
                8
            ]
        },
        {
            "company_name": "Kiniksa Pharmaceuticals, Ltd.",
            "industry": "Pharmaceuticals",
            "metric_type": "Global distribution network (markets served)",
            "metric_src_pdf_page": [
                8
            ]
        },
        {
            "company_name": "Kiniksa Pharmaceuticals, Ltd.",
            "industry": "Pharmaceuticals",
            "metric_type": "Clinical trial sites operating at year-end",
            "metric_src_pdf_page": [
                185,
                170
            ]
        },
        {
            "company_name": "Kiniksa Pharmaceuticals, Ltd.",
            "industry": "Pharmaceuticals",
            "metric_type": "Number of drugs on the market (approved)",
            "metric_src_pdf_page": [
                170
            ]
        },
        {
            "company_name": "Kiniksa Pharmaceuticals, Ltd.",
            "industry": "Pharmaceuticals",
            "metric_type": "Number of compounds in Phase III",
            "metric_src_pdf_page": [
                170
            ]
        },
        {
            "company_name": "Kiniksa Pharmaceuticals, Ltd.",
            "industry": "Pharmaceuticals",
            "metric_type": "Number of compounds in Phase I",
            "metric_src_pdf_page": [
                170
            ]
        },
        {
            "company_name": "Kiniksa Pharmaceuticals, Ltd.",
            "industry": "Pharmaceuticals",
            "metric_type": "Number of compounds in Phase II",
            "metric_src_pdf_page": [
                170
            ]
        },
        {
            "company_name": "Kiniksa Pharmaceuticals, Ltd.",
            "industry": "Pharmaceuticals",
            "metric_type": "Number of active pharmaceutical patents",
            "metric_src_pdf_page": [
                170
            ]
        }
    ],
    "events": [
        {
            "event_type": "has_new_product_launches",
            "events_src_pdf_page": [
                10,
                11
            ]
        },
        {
            "event_type": "has_strategic_restructuring",
            "events_src_pdf_page": [
                16,
                20
            ]
        },
        {
            "event_type": "has_rnd_investment_numbers",
            "events_src_pdf_page": [
                8,
                11
            ]
        },
        {
            "event_type": "has_executive_compensation",
            "events_src_pdf_page": [
                11,
                12
            ]
        },
        {
            "event_type": "has_new_product_launches",
            "events_src_pdf_page": [
                126,
                171,
                172
            ]
        },
        {
            "event_type": "has_guidance_updates",
            "events_src_pdf_page": [
                125,
                130,
                172
            ]
        },
        {
            "event_type": "has_executive_compensation",
            "events_src_pdf_page": [
                120,
                179
            ]
        },
        {
            "event_type": "has_rnd_investment_numbers",
            "events_src_pdf_page": [
                110,
                130
            ]
        }
    ],
    "fin_metrics": [
        {
            "fin_metric_type": "total revenue",
            "fin_metrics_src_pdf_page": [
                45,
                46
            ]
        },
        {
            "fin_metric_type": "net income",
            "fin_metrics_src_pdf_page": [
                45
            ]
        },
        {
            "fin_metric_type": "total assets",
            "fin_metrics_src_pdf_page": [
                46
            ]
        },
        {
            "fin_metric_type": "shareholders' equity",
            "fin_metrics_src_pdf_page": [
                46
            ]
        },
        {
            "fin_metric_type": "total liabilities",
            "fin_metrics_src_pdf_page": [
                46
            ]
        },
        {
            "fin_metric_type": "total revenue",
            "fin_metrics_src_pdf_page": [
                130,
                151
            ]
        },
        {
            "fin_metric_type": "net income",
            "fin_metrics_src_pdf_page": [
                155,
                168
            ]
        },
        {
            "fin_metric_type": "total assets",
            "fin_metrics_src_pdf_page": [
                153,
                157
            ]
        },
        {
            "fin_metric_type": "total liabilities",
            "fin_metrics_src_pdf_page": [
                154
            ]
        }
    ]
}